Montreal / April 19, 2024 - NexPlasmaGen is honored to announce that it has won GHP magazine's Best MedTech Oncology Business - Canada 2024 award. "GHP Magazine's Biotechnology Awards 2024” are designed to recognize and honor the most valuable contributors to the biotechnology industry, as well...
Montreal / April 05, 2024 - NexPlasmaGen is pleased to announce that on February 6, 2024, the 2nd U.S. patent (US 11895763B2) was granted for its medical technology developed for the treatment of breast cancer. NexPlasmaGen has exclusive rights to this patent under license from...
NEXPLASMAGEN TO PRESENT AT SEED SHOWCASE 2022 NexPlasmaGen will pitch its business opportunity to investors! Montreal/December 24 – NexPlasmaGen, today announced that it is presenting at Seed Showcase, part of the Biotech Showcase™ 2022 conference. This year, in addition to seeing NexPlasmaGen scheduled presentation delivered onsite via...
NexPlasmaGen is proud to announce that the preclinical trials program led by Dr. Philip Wong at the Centre Hospitaller de l’Université de Montréal was successfully completed. The first stage of the program demonstrated that NexPlasmaGen's Convertible Plasma Jet (CPJ) was able to destroy breast cancer...
NexPlasmaGen Inc. is pleased to announce the completion of $795,000 in private and public investment from individuals, Aligo Innovation, the Quebec MEDTEQ program and the federal MITACS and CNRC-IRAP programs to accelerate the development of its patented cold plasma technology, the APGDT, as an adjuvant...